Skip to main content

Market Overview

Mid-Day Market Update: Crude Oil Rises 1.5%; Mesoblast Shares Plunge

Share:

Midway through trading Friday, the Dow traded down 0.53% to 30,142.54 while the NASDAQ fell 0.29% to 12,727.34. The S&P also fell, dropping 0.48% to 3,704.47.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 17,213,880 cases with around 310,790 deaths. India confirmed a total of at least 9,979,440 confirmed cases and 144,780 deaths, while Brazil reported over 7,110,430 COVID-19 cases with 184,820 deaths. In total, there were at least 75,075,060 cases of COVID-19 worldwide with over 1,664,760 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Utilities shares rose by 0.1% on Friday. Meanwhile, top gainers in the sector included Korea Electric Power Corporation (NYSE: KEP), up 6%, and Enel Americas SA (NYSE: ENIA), up 5%.

In trading on Friday, real estate shares dipped 1.4%.

Top Headline

Darden Restaurants, Inc. (NYSE: DRI) reported stronger-than-expected earnings for its second quarter.

Darden posted quarterly earnings of $0.74 per share, beating analysts’ estimates of $0.71 per share. The company’s quarterly sales came in at $1.66 billion, versus expectations of $1.68 billion.

 

Equities Trading UP

Exela Technologies, Inc. (NASDAQ: XELA) shares shot up 41% to $0.512. Exela Technologies secured a term loan of $145 million.

Shares of CURO Group Holdings Corp (NYSE: CURO) got a boost, shooting 91% to $16.80. Katapult will go public through merger with FinServ Acquisition Corp. Katapult is 40% owned by CURO Group.

Mereo BioPharma Group plc (NASDAQ: MREO) shares were also up, gaining 88% to $4.16. Mereo BioPharma and Ultragenyx announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.

Equities Trading DOWN

Mesoblast Limited (NASDAQ: MESO) shares tumbled 34% to $8.99. Mesoblast said Data Safety Monitoring Board that performed a third interim analysis of data from a study of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome due to COVID-19 infection said the trial is not likely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment.

Shares of Scopus BioPharma Inc. (NASDAQ: SCPS) were down 36% to $21.86 after climbing 474% on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma priced its IPO at $5.5 per share.

Applied DNA Sciences, Inc. (NASDAQ: APDN) was down, falling 16% to $5.24 after the company reported downbeat quarterly results.

Commodities

In commodity news, oil traded up 1.5% to $49.09, while gold traded down 0.1% to $1,890.20.

Silver traded down 0.4% Friday to $26.075 while copper rose 0.6% to $3.6245.

Euro zone

European shares were lower today. The eurozone’s STOXX 600 fell 0.27%, the Spanish Ibex Index fell 1.25%, while Italy’s FTSE MIB Index declined 0.11%. Meanwhile, the German DAX 30 slipped 0.06%, French CAC 40 declined 0.37% and London’s FTSE 100 fell 0.21%.

German producer prices dropped 0.5% year-over-year in November following a 0.7% decline in the previous month, while retail sales in the UK dropped 3.8% in November.

Economics

The current account gap increased by 10.6% to $178.5 billion in the third quarter.

The index of leading economic indicators rose 0.6% for November.

The Baker Hughes North American rig count report for the latest week is scheduled for release at 1:00 p.m. ET.

 

Related Articles (APDN + CURO)

View Comments and Join the Discussion!

Posted-In: Earnings News Penny Stocks Eurozone Commodities Small Cap Global Intraday Update

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com